Plus Therapeutics Faces Nasdaq Compliance Notice

Plus Therapeutics ( (PSTV) ) just unveiled an update.

On May 21, 2025, Plus Therapeutics received a notice from Nasdaq due to a delay in filing its Quarterly Report for the period ending March 31, 2025, which resulted in non-compliance with Nasdaq Listing Rule 5250(c)(1). The company has until July 21, 2025, to submit a compliance plan, with a possible extension until November 17, 2025, if accepted. This notification does not immediately affect the company’s Nasdaq listing, and Plus Therapeutics is working to file the report promptly to regain compliance.

The most recent analyst rating on (PSTV) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.

Spark’s Take on PSTV Stock

According to Spark, TipRanks’ AI Analyst, PSTV is a Underperform.

Plus Therapeutics is facing significant financial challenges with consistent losses and negative equity, which are major risks. While there are positive future growth prospects from clinical trials and strategic financing efforts, the stock remains risky due to its current financial instability.

To see Spark’s full report on PSTV stock, click here.

More about Plus Therapeutics

Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for challenging central nervous system cancers. The company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases and recurrent glioblastoma, supported by strategic partnerships for development, manufacturing, and potential commercialization.

Average Trading Volume: 17,403,906

Technical Sentiment Signal: Sell

Current Market Cap: $5.32M

See more insights into PSTV stock on TipRanks’ Stock Analysis page.